SPY336.14+1.25 0.37%
DIA277.89+0.39 0.14%
IXIC11,261.00+93.49 0.84%

Co-Diagnostics, Inc. Enters Into Agreement With Arches Research To Expand COVID-19 Testing Services

SALT LAKE CITY, Sept. 8, 2020 /PRNewswire/ --Co-Diagnostics, Inc.(NASDAQ:CODX), (the Company), a molecular diagnostics company with a unique, patented platform for the development of diagnostic tests, today

· 09/08/2020 08:02

SALT LAKE CITY, Sept. 8, 2020 /PRNewswire/ --Co-Diagnostics, Inc.(NASDAQ:CODX), (the Company), a molecular diagnostics company with a unique, patented platform for the development of diagnostic tests, today announced that it has entered into an agreement with Arches Research, Inc, a CLIA laboratory and subsidiary of Polarity TE, Inc, (NASDAQ:PTE), to expand Arches' COVID-19 testing services using Co-Diagnostics' Logix Smart™ COVID-19 test kit.
 

Co-Diagnostics Official Logo (PRNewsfoto/Co-Diagnostics)

Arches Research began using Co-Diagnostics' tests for its customers earlier this year. The announcement follows news last week of additional, independent third-party validation of the Company's test, supporting its performance characteristics and value in helping communities, schools, and workplaces to re-open safely.

Dwight Egan, CEO of Co-Diagnostics, remarked, "We are pleased to have this opportunity to further expand our relationship with one of our valued CLIA lab clients to help meet demand for COVID-19 testing. Arches has been an important customer in the ongoing battle against the coronavirus, and we expect this agreement will also create opportunities for sales of additional molecular diagnostic products in our development pipeline, including our upcoming Logix Smart Flu A/Flu B/COVID-19 test kit."

The CE-marked and FDA EUA Co-Diagnostics Logix Smart COVID-19 test is currently available to all clinical laboratories certified under Clinical Laboratory Improvement Amendments (CLIA), and is authorized to be used for the diagnosis of SARS-CoV-2, the virus that causes COVID-19, in the US and many other countries.

Arches received a Clinical Laboratory Improvement Amendments of 1988 (CLIA) certificate of registration at the end of April and began testing for COVID-19 shortly thereafter. CLIA is regulated by the Centers for Medicare & Medicaid Services (CMS) with a primary goal to ensure quality laboratory testing.